🌟 Exciting News at MyoPharm ! 🌟 Another milestone has been etched intoMyoPharm’s journey! 🚀 After three years of anticipation, we're thrilled to announce that all four members of our MyoPharm family have finally been granted permanent residency. 🎉 This monumental event will shape the destiny of our entire team. A heartfelt thank you to Golden Dream, INGWE Immigration companies, Spark Center and Launchpath for their invaluable support throughout this journey. 🙏 Your guidance and assistance have been instrumental in making this dream a reality. Here's to brighter days ahead for every member of the MyoPharm family! #MyoPharm #PermanentResidency #GoldenDream #INGWE#Teamwork #MilestoneAchievement
MyoPharm
Biotechnology Research
innovative 3D-bioprinting technology to develop organs-on-chip
About us
MyoPharm is a biotechnology company that offers pharmaceutical companies a proven-effective method of analyzing their compounds during pre-clinical stages for clinical trial efficacy, thus presenting a significant cost-cutting opportunity and lowering attrition risk during the clinical trial stage. We are an innovative developer of 3D-bioprinting technology for the development of organs-on-chip for compound screening and tissue engineering. We will develop a prototype of the organ's tissue for further product testing, development, and market commercialization.
- Website
-
https://myopharm.ca
External link for MyoPharm
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Oshawa
- Type
- Privately Held
Locations
-
Primary
Get directions
2 Simcoe Street South
Suite 300
Oshawa, CA
Employees at MyoPharm
Updates
-
Explore the fascinating realm of organ-on-a-chip (OOC) technology in this video! Delve into the intricacies of how human cells craft organ and tissue replicas in vitro, fostering interconnectivity for meaningful organ crosstalk. Uncover the secrets of OOC's ability to provide cells with nutrients, oxygen, and biomechanical cues, mirroring the complexities of the human body. Watch and learn why OOC technology stands as a crucial preclinical tool. #Myopharm #OrganOnAChip #Biotechnology https://lnkd.in/eFQ52ein
-
As we near the close of 2023, reflecting on a dynamic year at Mayopharm. Grateful for the dedication of our team as we gear up for a promising start in Canada. Appreciate your continued support, looking forward to brighter days ahead in the new year! #Mayopharm
-
-
Addressing the pivotal issue of species differences between animals and humans, which contributes to the high failure rate of approximately 90% in clinical trials for drug candidates. It's time for a change. Our Organ-Chips emulate human responses more accurately than traditional models, enabling the advancement of superior drug candidates to clinical trials. Partner with our expert team to de-risk your drug development pipeline through a range of Organ-on-a-Chip compound testing services. Let's revolutionize drug development together. #Myopharm #DrugDevelopment #InnovationInHealthcare #OrganOnAChip
-
-
Grateful to the Spark group for their valuable time dedicated to Mayopharm. Mayopharm greatly benefits from the support and collaboration of experts acquainted with the Canadian market as we embark on establishing the company and navigating our initial stages. #Mayopharm #Collaboration #CanadianMarketExperts
-